language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
SBRASBRA

$18.68

-0.20
arrow_drop_down1.06%
Market closed·update13 Nov 2025 21:00
Day's Range
18.585-18.875
52-week Range
15.6-19.97

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-05
Next Earnings TimeAfter Market Close
Volume2.82M
Average Volume 30d2.75M

AI SBRA Summary

Powered by LiveAI
💰
25.5
Valuation (P/E Ratio)
Reasonable for growth sector
📈
0.152
EPS Growth (YoY)
Strong earnings growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
79

Sabra Health Care REIT demonstrates solid fundamental strength with a consistent dividend and a diversified portfolio. Thematic tailwinds in healthcare real estate are positive, though recent technicals suggest potential short-term price consolidation. Overall a balanced investment for income-focused investors.

Positive

Thematic

70

The company operates within the growing healthcare real estate sector, benefiting from demographic trends and increasing demand for senior housing and healthcare facilities.

Strong

Fundamental

85

Sabra exhibits strong profitability, consistent dividend payments, and a manageable debt structure, supported by stable revenue generation from its real estate assets.

Neutral to Cautious

Technical

65

The stock has shown recent volatility, trading below its 50-day moving average. While the long-term trend remains somewhat positive, short-term indicators suggest a period of consolidation or potential further decline.

FactorScore
Healthcare Demographics85
Diversification80
Healthcare Real Estate Market Trends75
Interest Rate Sensitivity55
FactorScore
Valuation65
Profitability80
Growth75
Balance Sheet Health70
Cash Flow95
FactorScore
Trend Analysis40
Momentum45
Volume Confirmation60
Support & Resistance70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent EPS Performance

Company has reported actual EPS equal to or exceeding analyst estimates in the last two reported quarters (2025 Q2 and 2025 Q1), indicating a track record of meeting or beating earnings expectations.

Valuation chevron_right

Attractive P/E Ratio Relative to Recent Performance

The trailing P/E ratio of 37.4 for TTM is high, but recent quarterly data shows improving net income and P/E ratios (e.g., 2025 Q1 P/E of 101.4, suggesting improvement from a higher base or anticipation of future growth).

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

High Trailing P/E Ratio

The trailing P/E ratio for TTM is 37.4, and for 2024, it is 31.4. While net income is positive, these multiples are high, especially considering past periods of net losses (e.g., 2022, 2021).

Growth Deceleration chevron_right

Inconsistent Revenue and Net Income Growth

Revenue growth has been inconsistent, from $569.545M in 2021 to $703.235M in 2024. Net income has fluctuated significantly, with a substantial net loss in 2022 (-$77.605M) and a lower net income in 2023 ($13.756M) compared to 2024 ($126.712M).

Show More 🔒

Calendar

May 2025

16

Ex-Dividend Date

May 2025

30

Next Dividend Date

August 2025

5

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.17

A: $0.17

L: $0.16

H: 188.31M

A: 186.27M

L: 185.20M

Profile

Employees (FY)50.0
ISINUS78573L1061
FIGI-

Sabra Health Care REIT, Inc. as of March 31, 2025 investment portfolio included 364 real estate properties held for investment (consisting of (i) 224 skilled nursing/transitional care facilities, (ii) 39 senior housing communities (senior housing - leased), (iii) 69 senior housing communities operated by third-party property managers pursuant to property management agreements (senior housing - managed), (iv) 17 behavioral health facilities and (v) 15 specialty hospitals and other facilities), 15 investments in loans receivable (consisting of three mortgage loans and 12 other loans), four preferred equity investments and two investments in unconsolidated joint ventures. As of March 31, 2025, Sabras real estate properties held for investment included 37,075 beds/units, spread across the United States and Canada.

Seasonals

2025
2024
2023
2022
2021

Price Target

19.75 USD

The 39 analysts offering 1 year price forecasts for SBRA have a max estimate of 21.00 and a min estimate of 18.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
234M (98.38%)
Closely held shares
3.87M (1.62%)
238M
Free Float shares
234M (98.38%)
Closely held shares
3.87M (1.62%)

Capital Structure

Market cap
4.37B
Debt
2.44B
Minority interest
0.00
Cash & equivalents
60.47M
Enterprise value
6.75B

Valuation - Summary

Market Cap
4.37B
Net income
117M(2.67%)
Revenue
544M(12.44%)
4.37B
Market Cap
4.37B
Net income
117M(2.67%)
Revenue
544M(12.44%)
Price to earning ratio (P/E)37.40x
Price to sales ratio (P/S)8.00x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
703.24M
COGS
227.09M
Gross Profit
476.15M
OpEx
219.69M
Operating Income
256.46M
Other & Taxes
129.75M
Net Income
126.71M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒